Detalhe da pesquisa
1.
Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.
BMC Health Serv Res
; 23(1): 553, 2023 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237256
2.
"As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.
Harm Reduct J
; 20(1): 51, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060027
3.
Collaboration between family physicians and nurse clinicians: opinions of graduates in family medicine.
Can Fam Physician
; 60(8): e416-22, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25122832
4.
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review.
Int J Drug Policy
; 117: 104058, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182352
5.
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.
Subst Abuse Treat Prev Policy
; 18(1): 56, 2023 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37777766
6.
The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC.
Subst Abuse Rehabil
; 14: 147-156, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38026787
7.
How Can We Raise Awareness of Physician's Needs in Order to Increase Adherence to Management and Leadership Training?
J Healthc Leadersh
; 13: 109-117, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33953630